# Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa)

Study · id `cardio:ct-nct02030054` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02030054](<https://clinicaltrials.gov/study/NCT02030054>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02030054

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT02030054. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT02030054, source copy `cardio:ctgov-nct02030054-2014-12-04`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02030054, source copy `cardio:ctgov-nct02030054-2014-12-04`, retrieved 2026-10-26)
- Primary completion: 2015-06 (anticipated) (ClinicalTrials.gov record NCT02030054, source copy `cardio:ctgov-nct02030054-2014-12-04`, retrieved 2026-10-26)
- Completion: 2015-09 (anticipated) (ClinicalTrials.gov record NCT02030054, source copy `cardio:ctgov-nct02030054-2014-12-04`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT02030054, source copy `cardio:ctgov-nct02030054-2014-12-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02030054-2014-12-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa)
- Acronym: gRANADa
- Condition: Coronary Artery Disease
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Rosuvastatin
- Lead sponsor: University of Roma La Sapienza
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: University of Roma La Sapienza (`cardio:org-university-of-roma-la-sapienza`)

## Provenance

Content hash: 3905fac2958b757469169501ed6b040c9fe02505c40aef1bf390d43f0b05f4ad
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
